Biovail acquires Vasotec®/Vaseretic® from Merck & Co.
By Business Review Editor
Pharma Deals Review: Vol 2002 Issue 25 (Table of Contents)
Published: 2 Jun-2002
DOI: 10.3833/pdr.v2002.i25.1054 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Biovail acquired the marketing and distribution rights to Vasotec (enalapril) and Vaseretic (enalapril with hydrochlorothiazide) from Merck & Co...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS